NetScientific (GB:NSCI) has released an update.
NetScientific, a deep tech and life sciences VC firm, reports that its portfolio company PDS Biotechnology is making strides in the medical field with a promising update on its Versamune® HPV cancer treatment. PDS Biotech has initiated a Phase 3 trial after positive Phase 2 results and plans to present updated trial data at upcoming medical conferences. Financially, the company has reduced its net loss compared to the previous year, with a solid cash reserve to support ongoing research.
For further insights into GB:NSCI stock, check out TipRanks’ Stock Analysis page.
